Metformin Aurobindo

Metformin Hydrochloride, the active ingredient in Metformin Aurobindo, is a biguanide presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus and related glucose‑handling disorders in adult patients. GNH USA supplies Metformin Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Aurobindo belongs to the biguanide class and is used to improve glycaemic control in disorders of glucose metabolism. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. - Prediabetes (impaired glucose tolerance): delays progression to overt diabetes. - Polycystic ovary syndrome: reduces insulin resistance and may improve menstrual regularity.

Metformin Aurobindo may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or loss of appetite. - Diarrhea: frequent loose stools, especially during treatment initiation. - Metallic taste: transient alteration in taste perception. - Flatulence: increased intestinal gas. - Weight loss: modest reduction in body weight.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening accumulation of lactate. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatotoxicity: abnormal liver enzymes indicating liver injury. - Vitamin B12 deficiency: may develop with long‑term therapy. - Hypoglycaemia: uncommon when used alone but possible with other glucose‑lowering agents.

Before initiating Metformin Aurobindo, clinicians should evaluate patient‑specific risk factors and monitor relevant parameters. - Renal function: assess creatinine clearance and avoid use in severe renal impairment. - Hepatic function: check liver enzymes; avoid in active liver disease. - Risk of lactic acidosis: consider comorbidities such as heart failure, hypoxia, or sepsis. - Elderly patients: start at lower doses and monitor tolerance closely. - Vitamin B12 status: periodic testing is advisable during prolonged therapy. - Store at room temperature: keep in the original container, protect from moisture and heat.

Metformin Aurobindo can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations. - Alcohol (excessive): enhances risk of lactic acidosis. - Diuretics (e.g., thiazides): may impair renal clearance of metformin.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - ACE inhibitors or ARBs: monitor renal function when combined. - Other antidiabetic agents (e.g., sulfonylureas): increase risk of hypoglycaemia. - CYP450 inhibitors (e.g., trimethoprim): may affect renal handling of metformin.